Natixis Advisors
ARRY

Natixis Advisors’s Array Biopharma Inc ARRY Stock Holding History

Natixis Advisors’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-10,562
Closed -$258K – 1096
2019
Q1 		$258K Buy
+10,562
New +$220K ﹤0.01% 1036

Other funds holding ARRY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Natixis Advisors's ARRY Position: Q2 2019 in Review

Natixis Advisors sold out of Array Biopharma Inc (ARRY) in Q2 2019, closing a stake of 10,562 shares — an estimated $258K sold.

Natixis Advisors first reported a position in ARRY in Q1 2019 and held it in 1 quarter. The position peaked at $258K in Q1 2019. 318 funds tracked by Wall St. Rank hold ARRY as of Q2 2019.

  • Natixis Advisors reported no remaining Array Biopharma Inc position as of Q2 2019 after selling out during the quarter.
  • Natixis Advisors sold 10,562 Array Biopharma Inc shares in Q2 2019, an estimated $258K.
  • Natixis Advisors first reported a position in Array Biopharma Inc in Q1 2019 and held it in 1 quarter.
  • Natixis Advisors's Array Biopharma Inc position peaked at $258K in Q1 2019.
  • 318 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2019.

Based on Natixis Advisors's 13F filing for Q2 2019, filed 12 Aug 2019.